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NanomedicineThe purposes of the present study were to further evaluate the biologic signiﬁcance of the CD22ΔE12 molecular
lesion and determine if it could serve as a molecular target for RNA interference (RNAi) therapy. We show that
both pediatric and adult B-lineage lymphoid malignancies are characterized by a very high incidence of the
CD22ΔE12 genetic defect. We provide unprecedented experimental evidence for a previously unrecognized
causal link betweenCD22ΔE12 and aggressive biology of BPL cells by demonstrating that siRNA-mediated knock-
down of CD22ΔE12 in primary BPL cells is associated with a marked inhibition of their clonogenicity. These ﬁnd-
ings provide the preclinical proof-of-concept that siRNA-mediated depletion of CD22ΔE12 may help develop
effective treatments for high-risk and relapsed BPL patients who are in urgent need for therapeutic innovations.
We also describe a unique polypeptide-based nanoparticle formulation of CD22ΔE12-siRNA as an RNAi thera-
peutic candidate targeting CD22ΔE12 that is capable of delivering its siRNA cargo into the cytoplasm of leukemia
cells causing effective CD22ΔE12 depletion andmarked inhibition of leukemic cell growth. Further development
and optimization of this nanoparticle or other nanoformulation platforms for CD22ΔE12-siRNAmay facilitate the
development of an effective therapeutic RNAi strategy against a paradigm shift in therapy of aggressive or
chemotherapy-resistant B-lineage lymphoid malignancies.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
CD22, a member of the Siglec (sialic acid-binding Ig-like lectins)
family of regulators of the immune system, is a negative regulator of
multiple signal transduction pathways critical for proliferation and
survival of B-lineage lymphoid cells. B-precursor acute lymphoblastic
leukemia (BPL) is the most common form of cancer in children and
adolescents. BPL cells express a dysfunctional CD22 due to deletion of
Exon 12 (CD22ΔE12) arising from a splicing defect associated with ho-
mozygous intronic mutations (Uckun et al., 2010). CD22ΔE12 results in
a truncating frame shift mutation yielding a mutant CD22ΔE12 protein
that lacks most of the intracellular domain including the key regulatory
signal transduction elements, such as the ITIMs that provide docking
sites for the SH2 domains of SHP1, and all of the cytoplasmic tyrosine
residues (Uckun et al., 2010). Our recent studies have demonstratedith Research Tower Suite 300-
LA Mailstop 160, Los Angeles,
du (F.M. Uckun).
. This is an open access article underthat CD22ΔE12 is a characteristic genetic defect of therapy-refractory
clones in pediatric BPL and implicated the CD22ΔE12 genetic defect in
the aggressive biology of relapsed or therapy-refractory pediatric BPL
(Ma et al., 2012). Furthermore, forced expression of CD22ΔE12 in trans-
genic mice causes fatal BPL, demonstrating that CD22ΔE12 alone is suf-
ﬁcient as an oncogenic driver lesion for malignant transformation and
clonal expansion of B-cell precursors (Uckun et al., unpublished data,
2014).
The purposes of the present study were to evaluate the biologic sig-
niﬁcance of the CD22ΔE12 molecular lesion in BPL and determine if it
could serve as a molecular target for RNA interference (RNAi) therapy.
Here we report that B-lineage lymphoid malignancies in children and
adults are characterized by a high incidence of the CD22ΔE12 genetic de-
fect. We further report a previously unrecognized causal link between
CD22ΔE12 and aggressive biology of BPL cells by demonstrating that
siRNA-mediated knockdown of CD22ΔE12 in primary BPL cells is associ-
ated with a marked inhibition of their clonogenicity. We also describe a
unique polypeptide-based nanoparticle formulation of CD22ΔE12-siRNA
as a ﬁrst-in-class RNAi therapeutic candidate targeting CD22ΔE12 that
is capable of delivering its siRNA cargo into the cytoplasm of leukemiathe CC BY license (http://creativecommons.org/licenses/by/3.0/).
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leukemic cell growth. Further development and optimization of this
nanoparticle may facilitate the development of an effective therapeutic
RNAi strategy against a paradigm shift in therapy of aggressive or
chemotherapy-resistant B-lineage lymphoid malignancies.
2. Methods
2.1. Gene Expression Proﬁling of Murine BPL Cells
Mouse leukemia cells were isolated frommarkedly enlarged spleens
of CD22ΔE12-Tg, BCR-ABL Tg or Eμ-MYC Tg mice, splenocytes from
wildtype healthy C57BL/6 mice served as controls. Total cellular RNA
was extracted from homogenized lysate samples of leukemia cells
using the Qiagen RNeasy Plus Mini Kit (catalog no. 74134) (Qiagen,
Santa Clarita, CA). In order tominimize the genomicDNA contamination
in the RNA samples, the homogenized lysate samples were ﬁrst run
through a DNA binding spin column prior to steps of RNA binding,
washing and elution. Total RNA (45 μL/sample) was obtained with a
concentration range of 60–200 ng/µL and an absorbance ratio (A260/
A280) ranging from 1.9–2.1. RNA quality as judged by the integrity of
the 28S and 18S ribosomal RNA was determined by an Agilent 2100
Bioanalyzer to ensure that it was acceptable for subsequent microarray
analysis. Gene expression values for splenocytes fromWT healthy C57/
BL/6 mice (N = 4), leukemia cells from CD22ΔE12-Tg mice (N = 2),
leukemia cells from BCR-ABL Tg mice (N = 2), and leukemia cells
from Eμ-MYC Tgmice (N=2)were estimated from RMAnormalization
of signal values following hybridization to the Affymetrix Mouse
Gene 1.0 ST Array (1,102,500 probes, 35,512 genes) (accession #s:
GSE58874 and GSE58872). PM signal values for probesets were extract-
ed utilizing raw CEL ﬁles matched with probe identiﬁers obtained from
a CDF ﬁle (MoGene-1_0-st-v1,r3.cdf obtained from http://www.aroma-
project.org/vignettes/GeneSTArrayAnalysis) implemented by Aroma
Affymetrix statistical packages run in the R-studio environment (ver-
sion 0.97.551, R-studio Inc., running with R 3.01). The PM signals were
quantiﬁed using Robust Multiarray Analysis (RMA) in a 3-step process
including RMA background correction, quantile normalization, and
summarization by a log additive model of probes in a probeset across
these samples (RmaPlm method adapted in Aroma Affymetrix). All ex-
pression values were log2 scaled. The RLE (Relative Log Expression) and
NUSE (Normalized Unscaled Standard Error) plots were utilized to as-
sess array quality. For each gene and each array, ratios were calculated
between the expression of a gene and the median expression of this
gene across all arrays of the experiment. Box plots of the RLE and
NUSE were within the quality bounds for all the arrays. Transcript
cluster annotations for the mouse array were obtained from NetAffx
website (http://www.affymetrix.com/Auth/analysis/downloads/na33/
wtgene-32_2/MoGene-1_0-st-v1.na33.2.mm9.transcript.csv.zip).
2.2. Phosphoproteome Analysis Using Antibody Microarrays
The Phospho Explorer Antibody Array (Full Moon BioSystems, Inc.,
Sunnyvale, CA) consists of 1330 duplicate spots interrogating 1318 pro-
teins (phosphorylated and unphosphorylated), housekeeping proteins
(beta actin, GAPDH), negative controls (N = 4), empty spots (N = 4)
and positive markers (N = 2). The antibodies are printed on standard-
size coated glass slides and can be scanned on all microarray scanners
that are compatible with 76 × 25 × 1 mm (3 in. × 1 in. × 1 mm) slides.
The antibody array analyses were performed on cell lysate protein
samples according to standard protocols. In brief, the cell lysates were
biotinylated for 2 h at room temperature using the Biotin reagent in
the antibody array assay kit (Full Moon BioSystems, Inc.). The array
slide was blocked with blocking solution for 30 min at room tempera-
ture on an orbital shaker and then rinsed ten times with Milli-Q grade
water. The biotinylated proteins (~80 μg) weremixedwith 6mL of cou-
pling solution (Full Moon Biosystems, Inc.) and then added over thearray slide for a 2-hour incubation at room temperature while shaking.
The arraywas thenwashedwith 30mL of 1×Wash Solution (Full Moon
Biosystems, Inc.) for 10 min for a total of three times and then rinsed ten
times with Milli-Q water before detection of bound biotinylated pro-
teins using Cy3-conjugated streptavidin. Subsequently, the array slide
was incubated in Cy3-Streptavidin solution for 30 min in the dark
while shaking. Next, the slide was washed with 1× Wash buffer and
rinsed withMilli-Q water as before. The slide was then dried with com-
pressed nitrogen and scanned using Axon GenePix 4000 scanner and
the images were analyzed with GenePix Pro 6.0 (Molecular Devices,
Sunnyvale, CA). The ﬂuorescence signal of each antibody was obtained
from the ﬂuorescence intensity of this antibody spot after subtraction
of the blank signal (spot in the absence of antibody). Two technical rep-
licates were performed for each sample. Median signal intensity for
each spot was extracted from array images and the average intensity
for each antibody reaction with the protein was determined for repli-
cate spots. Data were normalized utilizing the median intensity values
for the 1318 antibodies on each array (normalized data = average sig-
nal intensity of replicate spots / median signal). The normalized data
were log10 transformed and mean centered to the WT samples (N = 4,
2 technical replicates for each of 2 samples) (Accession #s: GSE58873
andGSE58874). Student's T-tests (unequal variance correction,Microsoft
Excel) compared mean-centered, log10 transformed protein expression
levels in BPL cells from CD22ΔE12-Tg mice vs. splenocytes from WT
mice and BPL cells from BCR-ABL Tg or MYC Tg mice. 142 phosphopro-
teins were differentially expressed with P-values b0.02 (false discovery
rate=18%; 99 of these proteinswere downregulated and 43were upreg-
ulated). Most signiﬁcant effect sizes were compiled by ﬁltering according
to fold changes greater than 1.1 and P b 0.02.
2.3. CD22ΔE12-driven Gene Expression Cassette
32 genes (represented by 43probesets) encoding the 34most signif-
icantly overexpressed proteins (including 2 phosphorylated forms of
JunB (JunB (Phospho-Ser259) and JunB (Phospho-Ser79))); and NFκB
(NFκB-p105/p50 (Ab-932), NFκB-p65 (Ab-435))), in CD22ΔE12-Tg
mice were identiﬁed by cross referencing the Swiss Prot ID provided
by the manufacturers of the antibody array with the Affymetrix
mogene10 annotation data provided by Bioconductor for R
(mogene10sttranscriptcluster.db ﬁle) as well as the conversion
tool provided by MGI, Jackson Laboratory (http://www.informatics.jax.
org/homology.shtml). These mouse probesets were compared for differ-
ential expression in 2 CD22ΔE12 mice versus 4 Wildtype mice utilizing
a Mixed Model ANOVA (lme4 package from R; 2 ﬁxed factors for
“probeset” and “genotype” (CD22ΔE12 and WT), 1 interaction term for
“probeset × genotype”, and 1 random factor formouse ID) to identify sig-
niﬁcantly affected mRNA levels (least square means and standard error
estimates calculated from the interaction term parameters) for the signif-
icantly affected proteins identiﬁed by the antibody array. Themouse gene
signature differentially expressed in CD22ΔE12-Tg mouse BPL cells com-
prised of 11 signiﬁcantly affected probesets representing 10 upregulated
genes and one downregulated gene. In order to examine the representa-
tion of this CD22ΔE12-dictated gene expression signature in human BPL
cells, we ﬁrst identiﬁed the human orthologs on the Affymetrix Human
Genome U133 Plus 2.0 Array (hgu133plus2.db ﬁle) downloaded from
the Bioconductor repository Affymetrix by cross-referencing the
hugene10 annotation data (hugene10sttranscriptcluster.dbﬁle) provided
by the Bioconductor repository for R software (http://www.bioconductor.
org/) as well as the conversion tool provided by MGI, Jackson Laboratory
(http://www.informatics.jax.org/homology.shtml). The CD22ΔE12-
driven gene expression cassette comprised of the 10 upregulated genes
in mouse BPL cells was represented in the transcriptome of human BPL
cells by 25 probesets for the human orthologs of the up regulated 10 sig-
nature genes. We compared the expression of these genes in normal
hematopoietic cells (N = 74, GSE13159) versus primary leukemia cells
BPL patients (N = 76, GSE28460, GSE18497), normal lymphoid cells
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leukemia cells from CLL patients (N = 578; GSE13159, GSE39671) and
normal lymphoid cells (N = 130) versus primary neoplastic cells from
mantle cell leukemia/lymphoma patients (MCL; N= 38, GSE36000) uti-
lizing the RMAnormalized database containing these subsets of adult and
pediatric leukemias. MixedModel ANOVAs (2 ﬁxed factors for “probeset”
and “diagnostic group”, 1 interaction term for “probeset × diagnostic
group” and 1 random factor for sample ID) were constructed for each
comparison to assess probeset level signiﬁcance (least square means
and standard error estimates obtained from the interaction term param-
eters) and signiﬁcance of the mouse gene signature as a whole for each
of the normal versus human leukemic group comparisons (least mean
squares and standard error estimates obtained from the “diagnostic
group” factor).
2.4. Determination of CD22ΔE12-index Values by Multiprobe Gene
Expression Proﬁling
We compiled archived transcriptome proﬁling datasets in the
Human Genome U133 Plus 2.0 Array platform regarding gene expres-
sion levels in primary leukemia cells from pediatric high-risk BPL pa-
tients and adult patients with chronic lymphocytic leukemia [CLL],
mantle cell leukemia/lymphoma [MCL], or Burkitt's lymphoma (BL).
To enable comparison of samples across studies, 2 sets of normalization
procedures were performed that merged the raw data. Perfect Match
(PM) signal values for probesets were extracted utilizing raw CEL ﬁles
matched with probe identiﬁers obtained from the Affymetrix provided
CDF ﬁle (HG-U133_Plus_2.cdf) implemented by Aroma Affymetrix
statistical packages ran in R-studio environment (version 0.97.551,
R-studio Inc., running with R 3.01). The PM signals were quantiﬁed
using Robust Multiarray Analysis (RMA) in a 3-step process including
RMA background correction, quantile normalization, and summariza-
tion by Median Polish of probes (RMA method adapted in Aroma
Affymetrix). RMA background correction estimates the background by
a mixture model whereby the background signals were assumed to be
normally distributed and the true signals are exponentially distributed.
Normalization was achieved using a two-pass procedure. First the
empirical target distribution was estimated by averaging the (ordered)
signals over all arrays, followed by normalization of each array toward
this target distribution.
BLAT analysis on CD22 probe sequences for probeset 217422_s_at
(covering exons 10–14) deposited in the Affymetrix NetAffx™ Analysis
Center (http://www.affymetrix.com/analysis/index.affx) was mapped
onto speciﬁc CD22 exons and visualized using the UCSC genome browser
(http://genome.ucsc.edu/cgi-bin/hgBlat?command=start). This analysis
was designed to locate ≥25-bp long sequences with ≥95% similarity in
the entire genome. The BLAT-based exon designations according to
3 reference sequences (viz.: UCSC genes, Ensembl gene predictions,
Human mRNA Genbank) were as follows: HG-U133_PLUS_2:217422_
S_AT_11 aligned to chr19: 35837525–35837549 (Exon 14); HG-U133_
PLUS_2:217422_S_AT_10 aligned to chr19: 35837478–35837502 (Exon
14); HG-U133_PLUS_2:217422_S_AT_8 aligned to chr19: 35837100–
35837124 (Exon 13); HG-U133_PLUS_2:217422_S_AT_9 aligned to
chr19: 35837117–35837139 (Exon 13); HG-U133_PLUS_2:217422_
S_AT_7 aligned to chr19:35836590–35836614 (Exon 12); HG-U133_
PLUS_2:217422_S_AT_6 aligned to chr19:35836566–35836590 (Exon
12); HG-U133_PLUS_2:217422_S_AT_5 aligned to chr19:35836535–
35836559 (Exon 12); HG-U133_PLUS_2:217422_S_AT_4 aligned to
chr19:35835979–35836003 (Exon 11); HG-U133_PLUS_2:217422_
S_AT_3 aligned to chr19:35835811–35835960 (Exon 11); HG-
U133_PLUS_2:217422_S_AT_2 aligned to chr19:35835741–35835765
(Exon 10). Background corrected and RMA-normalized signal values
for each probe in each sample were log2 transformed and median cen-
tered across 11 probes per sample. An Exon 12 Index was calculated by
subtracting the median centered expression values of the Exons 10–11
plus Exons 13–14 probes from the median centered expression valuesof the Exon 12 probes. The CD22ΔE12 index values were calculated
and compared for, (i) normal bone marrow hematopoietic cells vs. pri-
mary leukemia cells from high-risk BPL patients, including multi-
lineage leukemia gene rearranged (MLL-R+) (N = 95; GSE11877,
GSE13159, GSE13351), BCR-ABL+ (N = 123; GSE13159, GSE13351)
and E2A-PBX1+ patients (N = 61; GSE11877, GSE13159, GSE13351),
(ii) and adult leukemia/lymphoma cells from patients with chronic
lymphocytic leukemia (CLL) (N = 578; GSE13159, GSE39671), mantle
cell lymphoma/leukemia (MCL) (N=38; GSE36000) and Burkitt's lym-
phoma/leukemia (BL) (N= 5; GSE12453) vs. normal B-cells (N= 130;
GSE10846, GSE12195, GSE12453, GSE13159). To compare the incidence
of CD22ΔE12 in subsets of patients the proportion of leukemic samples
below the lower 95% Conﬁdence interval for normal non-leukemic cells
vs. leukemia/lymphoma cells for each patient sub-population was de-
termined. One-way ANOVA followed by Dunnett's post hoc method
was utilized to calculate P-values of the comparisons. Dot plots of the
sample level CD22ΔE12-index values depicted the proportion of ex-
pression values below the lower 95% conﬁdence intervals for the nor-
mal samples.
2.5. RT-PCR Analysis of Human Leukemia Cells for CD22ΔE12 mRNA
Expression
Reverse transcription (RT) and polymerase chain reaction (PCR)
were used to examine expression levels of wildtype CD22 and
CD22ΔE12 transcripts in human leukemia cells, as previously described
(Uckun et al., 2010; Ma et al., 2012). Total cellular RNA was extracted
from ALL cells using the QIAamp RNA Blood Mini Kit (catalog no.
52304) (Qiagen, Santa Clarita, CA, USA) following the manufacturer's
instructions. Oligonucleotide primers were obtained from Integrated
DNA Technologies (IDT, San Diego, CA, USA). The P7 primer set (Fwrd:
5′-GCCAGAGCTTCTTTGTGAGG-3′ and Rev: 5′-GGGAGGTCTCTGCATCTC
TG-3′) ampliﬁes a 182-bp region of the CD22 cDNA extending from
Exon 11 to Exon 13 and deletion of Exon 12 results in a smaller
CD22ΔE12-speciﬁc PCR product of 63-bp size using this primer set.
The P10 primer set was used as a positive control to amplify a 213-bp
region of the CD22 cDNA in both wildtype CD22 and CD22 with ΔE12
(Fwrd: 5′-ATCCAGCTCCCTCCAGAAAT-3′ and Rev: 5′-CTTCCCATGGTG
ACTCCACT-3′). Qiagen One-Step RT-PCR Kit (catalog no. 210212)
(Qiagen, Santa Clarita, CA, USA) was used following manufacturer's in-
structions to amplify the target PCR products. The conditions were
1 cycle (30 min 50 °C, 15 min 95 °C) and 35 cycles (45 s 94 °C, 1 min
60 °C, 1 min 72 °C). PCR products were separated on a 2% agarose gel
containing ethidium bromide. Gel images were taken with an UVP dig-
ital camera and a UV light in an Epi Chemi II Darkroom using the
LabWorks Analysis software (UVP, Upland, CA).
2.6. Leukemia Cells
We used 3 ALL xenograft clones derived from spleen specimens of
xenografted NOD/SCID mice inoculated with leukemia cells from pedi-
atric BPL patients. The secondary use of leukemic cells for subsequent
laboratory studies did not meet the deﬁnition of human subject re-
search per 45 CFR 46.102 (d and f) since it did not include identiﬁable
private information, and it was approved by the IRB (CCI) at the
Children's Hospital Los Angeles (CHLA) (CCI-10-00141; CCI review
date: 7-27-2010; IRB approval: 7-27-2010). Human Subject Assurance
Number: FWA0001914. We also used the ALL-1 (Ph+ adult BPL),
DAUDI (Burkitt's lymphoma/B-cell ALL) and RAJI (Burkitt's
lymphoma/B-cell ALL) cell lines.
2.7. Colony Assays
The effects of the transfections with CD22ΔE12-siRNA vs. scrambled
(scr)-siRNA, treatments with nanoformulations of CD22ΔE12-siRNA vs.
scr-siRNA on BPL xenograft clones or the CD22ΔE12+ leukemia cell
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et al., 1987). Cells were treated with the respective reagents for 24 h
at 37 °C. Immediately after transfection or completion of the 24 h
treatments, cells (0.5 × 106 cells/mL) were suspended in RPMI sup-
plemented with 0.9% methylcellulose, 30% fetal calf serum, and 2 mM
L-glutamine. Controls included untreated cells. Duplicate–quadruplicate
1mL samples containing 0.5 × 106 cells/samplewere cultured in 35mm
Petri dishes for 7 d at 37 °C in a humidiﬁed 5% CO2 atmosphere. On day
7, colonies containing ≥20 cells were counted using an inverted Nikon
Eclipse TS100 microscope. For colony assays of primary leukemia cells,
we substituted RPMI with alpha-MEM and FBS with calf
bovine serum. Colony images were taken using a Digital Sight DS-
2MBW Nikon camera.
2.8. Preparation of a Human Full-length CD22 and CD22ΔE12–14 Plasmids
The cDNA fragments encoding either full-length CD22 (CD22FL) or
truncated CD22 lacking exons 12–14 (CD22ΔE12–14) were generated
by PCR ampliﬁcation using the Phusion High Fidelity PCR Kit (New
England Biolabs, catalog no. E0553L) with the following primer sets:
full-length Fwd/Rev 5′-CTTGGTGCTAGCATGCATCTCCTCGGC-3′/5′
CCGGTCTCGAGGATGTTTGAGGATCACATAGTC-3′, and truncation ΔE12–
14 Fwd/Rev 5′-CTTGGTGCTAGCATGCATCTCCTCGGC-3′/5′-CCGGTCTCG
AGCCTTTTTATTCCTCAC-3′. The correct PCR products (FL: 2541-bp and
ΔE12–14: 2208-bp) were ligated into the 8497-bp lentiviral vector
pCL6-2AEGwo through the NheI and XhoI restriction sites (underlined)
using the Quick Ligase kit (New England Biolabs catalog no. M2200L)
following the manufacturer's instructions. The pCL6-2AEGwo lentiviral
backbone vector, a kind gift from Dr. Zanxian Xia, School of Biological
Science and Technology, Central South University, Changsha, Hunan
410078, China, contains both a “ribosome-skip” fragment encoding the
2A-like peptide APVKQTLNFDLLKLAGDVESNPGP and an in-frame eGFP
ﬂuorescent coding sequence downstream of a multiple cloning site.
The expression of GFP allows transduced cells to be identiﬁed using ﬂuo-
rescent microscope. The correct clones were ﬁrst conﬁrmed through re-
striction enzyme digestion and then characterized by sequencing the
backbone-insert junctions on both 5′ (83-bp upstream) and 3′ (74-bp
downstream) ends with the forward primer 5-CAGCCTGCTTCTCGCTTC
TGTT-3′ and the reverse primer 5′-CTCCTGCCAACTTGAGAAGGTC-3′per-
formed byGENEWIZ, Inc. (South Plainﬁeld, NJ) using Applied Biosystems
BigDye version 3.1. In this procedure, 3′-ﬂuorescent-labeled dideoxy-
nucleotides (dye terminators) were incorporated into DNA extension
products (cycle sequencing). The resultedDNA sequenceswere analyzed
by BioEdit v7.2.0 (http://www.mbio.ncsu.edu/bioedit). Plasmids with
conﬁrmed insertswere transformed to and propagated in chemical com-
petent DH5α strain of Escherichia coli cells. Milligrams of plasmid DNA
was extracted and puriﬁed from an approximately 100 mL of the bacte-
rial culture using Invitrogen PureLink® HiPure Plasmid Filter Maxiprep
Kit (catalog no. K2100-17) following manufacture's instruction. Plasmid
DNA quality and quantity was determined using Thermo Scientiﬁc
NanoDrop 2000 spectrophotometer. For the generation of infectious
lentiviral particles, the pCL6-2AEGwo lentiviral vectors containing either
the CD22 FL or CD22ΔE12–14 expression cassettes were co-transfected
with the ViraPower™ packaging plasmid mixture (K4975-00,
Invitrogen) into 293T cells using the BioT™ transfection reagent
(BioLand Scientiﬁc, CA). Supernatants of 293T cells were harvested
72 h later, ﬁltered (pore size, 0.22 μm), and viral particles were
concentrated by ultracentrifugation (120,000 ×g for 3 h at 4 °C).
The supernatants were discarded; the remaining viral pellets were
resuspended in 100 μL OptiMEM by gentle pipetting, aliquoted, and
stored at −80 °C until use. Infectious titers of the Lentivirus stocks
were determined by biological titration, in which 293T cells in a
24-wells plate were transduced with serial dilutions (1:10, 1:100,
1:1000) of the Lentivirus stock. Titers of all viral stocks were equalized
by adjusting the concentration of viral particles to 5 × 106 transduction
units (t.u.)/mL. For transduction of leukemia cells, 1 × 105 cells at loggrowth phase were incubated with lentiviral particles (20 μL) and 2 μL
polybrene (0.1 mg/mL) (Sigma-Aldrich) in a ﬁnal volume of 100 μL for
3 h. Transduced cells were examined for colony formation in a semi-
solid methylcellulose culture system to determine the effects of trans-
duction on their in vitro clonogenicity (number of colonies/105 cells
plated) and proliferative activity (number of cells/colony), as described
(Uckun et al., 1987).2.9. Animal Research Approval
The animal research inmicewas conducted according to Institution-
al Animal Care and Use Committee (IACUC) Protocols 280–12 and
293–10 that were approved by the IACUC of CHLA. All animal care pro-
cedures conformed to the Guide for the Care and Use of Laboratory An-
imals (National Research Council, National Academy Press, Washington
DC 1996, USA).2.10. Construction of pEμ-SR-R3Y Yeast Cloning Vector and
pEμ-SR-CD22ΔE12 Transgenic Expression Vector
We established a new CD22ΔE12 transgenic mouse model using a
novel transgenic expression vector designated ‘pEμ-SR-CD22ΔE12’
(accession # LM652705). The pEμ-SR backbone plasmid (Gabrielson
et al., 2012; Lu et al., 2011) containing the mouse IgH enhancer (Eμ)
and the potent SRα mammalian promoter (Yin et al., 2013a) along
with SV40 polyA termination sequences was kindly provided by Dr.
Jerry Adams (WEHI, Melbourne, Australia). Pronuclear microinjection
of the human CD22ΔE12 transgene, founder generation, and genotyp-
ing analysis of tail DNA were performed under a service contract at
the UC Davis Mouse Biology Program using standard methods. The
5.3-kb [promoter\ CD22ΔE12 cDNA-poly A] fragment of the pEμ-SR-
CD22ΔE12 transgene construct was microinjected into the pronuclei
of freshly fertilized oocytes from C57BL/6J mice. Injected oocytes were
transferred to day 0.5 postcoitus (dpc) pseudopregnant CD-1/Crl
females to generate CD22ΔE12-Tg mice. Founders were mated to
C57BL/6J mice obtained from Jackson Laboratories; CD-1/Crl mice
were obtained from Charles River laboratories. All mouse procedures
were carried out in accordance with the Institutional Animal Care and
Use Committee at the University of California, Davis (IACUC #15723).
Tg founder mice were identiﬁed by PCR analysis of genomic tail DNA.
Tg male mice were crossed to age-matched wildtype female C57BL/6
mice to produce transgenic lines and pups were screened for the pres-
ence of the transgene by PCR analysis of tail-extracted DNA. We also
performed RT-PCR to conﬁrm the expression of the CD22ΔE12 trans-
gene transcript in splenocytes from pre-leukemic CD22ΔE12-Tg mice
as well as BPL cells isolated from leukemic CD22ΔE12-Tg mice by
using a 5′CD22ΔE12E10primer (E10-F) and a 3′ vector backbone prim-
er (CD22ΔE12Tg-R2) to amplify a segment of the transgene message
spanning CD22ΔE12 exons 10, 11, 13, and 14. Total RNA was extracted
from splenocytes of wild type and CD22ΔE12-Tgmice using the RNeasy
Plus Mini Kit (catalog no. 74134, Qiagen, CA). A semi-quantitative RT-
PCR reaction was carried out where the ﬁrst-strand cDNA was synthe-
sized using SuperScript III (catalog no. 18080-051, Invitrogen CA) and,
the second PCR reaction was performed using the Phusion High-
Fidelity PCR Master Mix Kit (New England Biolabs) and the following
thermal cycling conditions: initial denaturation 98 °C × 30 s, 35 cycles
of denaturation 98 °C × 10 s, annealing 60 °C × 10 s and extension
72 °C × 30 s. The primers that speciﬁcally detect the 3′ end of
CD22ΔE12 transgene were: Fwd: E10-F: ATCCTCATCCTGGCAATCTG
and Rev: CD22ΔE12Tg-R2: 5′-CACCACCTTCTGATAGGCAGCC-3′ (es-
timated amplicon size: 436-bp). To ensure the quality and quantity
of the 1st strand cDNA, a fragment of the mouse β-Actin cDNA was also
ampliﬁed yielding a 206-bp product with primers Fwd 5′-CCTCTATGCC
AACACAGTGC-3′, Rev 5′-CCTGCTTGCTGATCCACATC-3′.
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Eμ-Myc Tg male founders (B6.Cg-Tg [IgHMyc] 22Bri/J, hemizygous
for Tg [IgHMyc] 22Br, JAXEAST: AX12) were obtained from the Jackson
Laboratory (Bar Harbor, Maine). These mice were bred to wildtype
female C57BL/6J mice to establish a colony of Eμ-Myc transgenic mice
(Harris et al., 1988). For genotyping of Eμ-Myc Tg mice, DNA was ex-
tracted from approximately 3 mm tail snips using Qiagen DNEasy
blood and tissue kit following the manufacturer's instructions. DNA
was then screened for theMyc transgene via TaqMan® qPCR via the rel-
ative Ct method multiplexed with the following oligos: Transgenic tar-
get primers/probe include a forward primer ATGTGCGCGGAACCCCTA
TT, reverse primer GGGCGACACGGAAATGTTG, and probe 6Fam-ACAT
TCAAATATGTATCCGCTCATGAGACA-NFQ and were quantiﬁed next
to endogenous reference primers/probe including a forward primer
GTCATCAAGTGAGAAAGACATCCT, reverse primer CATCATGAATTTTG
ATAAGCCCATT, a TaqMan probe CTCCTGGCTGCCTGGCTGGC with a 5′
VIC label (4,7,2′-trichloro-7′-phenyl-6-carboxyﬂuorescein) as ﬂuores-
cence reporter and a 3′ TAMRA label (6-carboxytetramethylrhodamine)
as quencher. Brieﬂy, 2 μL of each DNA sample was tested in a total reac-
tion volume of 10 μL utilizing Qiagen QuantiTect PCR kit with ROX
chemistry. 384 plates were processed on an AB7900HTwith the follow-
ing cycles: 95 °C for 15 min and then 40 cycles of 95 °C for 30 s, and
60 °C for 1 min. Each DNA sample ΔCt was compared against the
ΔCt of a transgenic mutant animal as well as a transgenic negative
(wildtype) DNA sample using AB RQ Manager 1.2.1 software. Likewise,
commercial BCR-ABL Tg [B6.Cg-Tg(BCR/ABL)623Hkp/J] mice were also
obtained from the Jackson Laboratory. The BCR-ABL Tg mice contain
the truncated murine metallothionein-1 promoter driving the expres-
sion of the 190-kDa BCR-ABL fusion protein characteristic of the
t(9;22) BPL. These mice were bred to wildtype female C57BL/6J mice
to establish a colony of BCR-ABL transgenic mice. Pups were screened
for the presence of the BCR-ABL transgene by PCR analysis of tail DNA
with a BCR-ABL Tg forward primer AGAGATCAAACACCCTAACCT and a
BCR-ABL Tg reverse primer CCAAAGCCATACTCCAAATGC for an expect-
ed BCR-ABL Tg amplicon of 417-bp. Both transgenic mouse lines devel-
op fatal BPL. Leukemic splenocytes from these commercial transgenic
mice that developed fatal leukemia with massive splenomegaly were
isolated at the time of the necropsy and subjected to gene expression
proﬁling and phosphoprotein proﬁling in side by side comparison
with CD22ΔE12-Tg BPL cells.
2.12. RNAi knockdown of CD22ΔE12 expression
CD22ΔE12-siRNA has been designed to speciﬁcally target the Exon
11 and Exon 13 junction of the CD22ΔE12 mature mRNA produced by
aberrant splicing of the CD22ΔE12 pre-mRNA with intronic mutations.
The speciﬁc CD22ΔE12 S-oligos were synthesized and puriﬁed with a
reverse phase cartridge at GeneLink (Hawthorne, NY). The CD22ΔE12-
siRNA duplex (MW: 13,492) was custom synthesized by GeneLink as
a single strand oligo and annealed after all deprotection and puriﬁcation
steps were completed. The segment of the mutant human CD22ΔE12
mRNA that stretches +/−20-bp from the Exon 11–Exon 13 junction
was used as a target sequence to generate potential siRNA candidates
using an algorithm provided by siDESIGN Center (GE Dharmacon, Lafa-
yette, CO) with default parameters settings. Three AA-motif (N19-mer)
target (sense) sequences covering the breakpoint (underlined)
were initially selected, these are: 5′-AAAGAGATGCAGAGTCCTC-3′,
5′-GAGATGCAGAGTCCTCAGA-3′, and 5′-AAGAGATGCAGAGTCCT
CA-3′. Phosphorothioate modiﬁcation (denoted as “*”) was imple-
mented for the ﬁrst and the last 3 nucleotides of the 5′ and 3′
ends, respectively, followed by addition of 3′ end TT overhang. The
sequence of the CD22ΔE12 antisense S-oligo was 5′-G*A*G*GACU
CUGCAUCUC*U*U*UTT-3′ and the sequence of the corresponding
sense oligo in the siRNA duplex was 5′-A*A*A*GAGAUGCAGA
GUC*C*U*CTT-3′. To document the speciﬁcity of the antisenseS-oligos we used appropriate scrambled (scr) control S-oligos with
the same modiﬁcation custom-prepared by GeneLink (antisense
5′-A*C*G*UGACACGUUCGGA*G*A*ATT-3′; sense 5′-U*U*C*UCCGA
ACGUGUCA*C*G*UTT-3′). The transfection of ALL-1 cells and BPL xe-
nograft cells with CD22ΔE12-siRNA and control/scrambled siRNA
was accomplished using the Amaxa Cell Line Nucleofector Kit T (cat-
alog no. VCA-1002, Lonza, Cologne, Germany) and a Nucleofector II
device according to a protocol speciﬁcally designed for the transfec-
tion of human B-lineage lymphoid cells (VCA-1002/C005) following
the manufacturer's recommendations. Approximately 2–5 × 106
cells were transfected with 50 nM (unless otherwise indicated)
CD22ΔE12-siRNA. Controls included untransfected cells and cells
transfected with scr-siRNA. An aliquot of the cells was transferred
to a 6-well plate with 1.5 mL pre-warmed RPMI culture medium
then kept overnight at 37 °C. The transfection efﬁciency was
conﬁrmed to be N50% by transfecting cells with Green transfection
indicator or siGlo™ (Thermo Scientiﬁc Dharmacon, D-001630-01-
05) and by counting the green ﬂuorescent cells. RNAi knockdown
of CD22ΔE12 expression was documented by RT-PCR analysis of
RNA samples using the P7 (WT: 182 bp, Mutant: 63 bp) and P10
(213 bp, control) primer pairs after 48 h and Western blot analysis
of whole cell lysates after 72 h, as described (Ma et al., 2012).
2.13. CD22ΔE12-siRNA nanoparticles
By using a 200-mer of the cationic cell-penetratingα-helical peptide
poly(γ-(4-vinylbenzyl)-L-glutamate/PVBLG)-8 (Gabrielson et al., 2012;
Lu et al., 2011) and previously published procedures for preparing
PVBLG-8 based nanoformulations of siRNA (Yin et al., 2013a),
we developed a nanoformulation of CD22ΔE12-speciﬁc siRNA. The
negatively charged siRNA was complexed with the positively charged
PVBLG-8 at the optimal weight ratio of 20 via electrostatic interactions
(Gabrielson et al., 2012; Lu et al., 2011; Yin et al., 2013a). PVBLG-8
was synthesized via hexamethyldisilazane (HMDS)-initiated controlled
ring opening polymerization of γ-(4-vinylbenzyl)-L-glutamate NCA
(VB-L-Glu-NCA) followed by side-chain vinyl group oxidation to alde-
hyde and amination (Gabrielson et al., 2012; Lu et al., 2011; Yin et al.,
2013a). Another polyanion (PAOBLG) (Zhang et al., 2011) was also in-
corporated at the optimal PAOBLG/siRNA weight ratio of 2 to further
stabilize the nanostructure and strengthen the electrostatic interactions
of the cationic PVLG-8 with the CD22ΔE12-siRNA. Cyanine dye Cy3 has
amaximumexcitation at 550 nm and emits maximally in the red end of
the spectrum at 570 nm. We used 5′ Cy3-labeled CD22ΔE12-siRNA to
prepare a PVLG-8 based CD22ΔE12-siRNA formulation for cellular up-
take and trafﬁcking experiments using confocal imaging. The Cy3-
labeled CD22ΔE12-siRNA duplex was custom-prepared by Integrated
DNA Technologies, Inc. (Coralville, Iowa). This material was used to
prepare a CD22ΔE12-siRNA nanoparticle formulation (NPF) for cellular
uptake and trafﬁcking experiments using confocal imaging. The ability
of the nanoparticles to knock down CD22ΔE12 expression was exam-
ined using RT-PCR (Ma et al., 2012) and their anti-leukemic activity
against CD22ΔE12-positive human leukemia cell line ALL-1 was evalu-
ated using colony assays (Uckun et al., 1987).
2.14. Physicochemical characterization of siRNA containing nanoparticles
Size measurement by the dynamic light scattering (DLS) technique
was performed on a DynaPro Titan Instrument (Wyatt Technology
Corp., Santa Barbara, CA) at the USC Nano BioPhysics Laboratory
(Uckun et al., 2013). We used the Quant-IT RiboGreen RNA assay
(Invitrogen) and a Synergy HT Biotek ﬂuorescence microplate reader
to measure the siRNA content of the PVLG-8 based nanoparticles. The
presence of siRNA in the formulationswas also conﬁrmed in 2% agarose
gels prepared using 0.5 μg/mL of ethidium bromide and 3% SDS that al-
lows staining of the siRNA contentwith ethidiumbromide. A 2% agarose
gel was prepared using UltraPure Agarose and 0.5 μg/mL of ethidium
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mersed in 1× TBE buffer and run in a horizontal electrophoresis system
(Bio-Rad, Mini-Sub Cell GT cell) for 1 h at 60 V. We used the 1 kb Plus
DNA ladder (Invitrogen) as size markers. Samples were prepared in
RNase-Free water (Qiagen, Valencia, CA) and 6× DNA loading buffer
(Bioland Scientiﬁc, Paramount, CA). After sample migration down the
gel, gel images were taken with an UVP digital camera and UV light in
an Epi Chemi II Darkroom using the LabWorks Analysis software
(UVP, Upland, CA).
2.15. Confocal laser scanning microscopy
Subcellular localization of Cy3-labeled CD22ΔE12-siRNA delivered
in the PVLGB-8 based hybrid nanoparticles was examined by immuno-
ﬂuorescence and spinning disk confocal microscopy using previously
described procedures for slide preparation and imaging (Uckun et al.,
2012). Cyanine dye Cy3 has a maximum excitation at 550 nm and
emitsmaximally in the red end of the spectrumat 570 nm. After incuba-
tion with the PVBLG-8 based formulation of Cy3-labeled siRNA for 6 h,
the internalized Cy3-labeled CD22ΔE12-siRNA was detected and local-
ized using the tetramethyl rhodamine (TRITC) ﬁlter sets since the exci-
tation and emission spectra are very close to those of TRITC. Slides were
imaged using the PerkinElmer Spinning Disc Confocal Microscope and
the PerkinElmer UltraView ERS software (Shelton, CT) or the Volocity
V5.4 imaging software (PerkinElmer, Shelton, CT). The coverslips were
ﬁxed with ice-cold MeOH at −20 °C for 10 min. Cells were stained
with a mouse monoclonal anti-tubulin antibody (Sigma catalog no.
T6199; Sigma-Aldrich, St. Louis, MO) for 1 h at room temperature.
Cells were washed with PBS and incubated with green-ﬂuorescent
Alexa Fluor 488 dye-labeled goat anti-mouse IgG (secondary Ab)
(catalog no.: A11001, Invitrogen, Carlsbad, CA) for 1 h. Cells were then
washed with PBS and counterstained with the blue ﬂuorescent DNA-
speciﬁc nuclear dye 4′,6-diamidino-2-phenylindole (DAPI). The cover-
slips were inverted, mounted onto slides in Vectashield (Vector Labs,
Burlingame, CA) to prevent photobleaching, and sealed with nail
varnish. UltraCruz Mounting Medium containing 1.5 μg/mL of DAPI
was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
2.16. Immunoﬂuorescence staining and ﬂow cytometric analysis of ALL
xenograft cells
A panel of commercially available monoclonal antibodies was used
for immunophenotyping of leukemic cells from spleen specimens of
NOD/SCID mice xenografted with primary human ALL cells by standard
immunoﬂuorescent staining and multiparameter ﬂow cytometry as
previously reported (Uckun et al., 2013). The antibodies were obtained
from BD Biosciences (San Jose, CA) and included: HLA/DR/DP/DQ FITC:
catalog no.: 555558, HLA-A,B,C Phycoerythrin: catalog no.: 555553,
CD10 (APC) BD catalog no.: 340923, CD19 (APC-H7) clone: SJ25C1 BD
catalog no.: 560177, CD34 (Per CP-Cy5.5) BD catalog no.: 347203, and
CD45 (V450) clone: H130 BD catalog no.: 560367. The labeled cells
were analyzed on a LSR II ﬂow cytometer (Becton Dickinson, Lakes,
NJ). Controls included unstained cells as well as cells that were stained
with a cocktail of control mouse IgG labeled with PE, FITC, APC, APC-
H7, and PerCP-Cy5.5. The labeled cells were analyzed on a LSR II ﬂow
cytometer (Becton Dickinson, Lakes, NJ).
3. Results
3.1. High incidence of the CD22ΔE12 genetic defect in B-lineage lymphoid
malignancies
A CD22ΔE12-index was calculated by subtracting the median
centered expression values of the 7 probes for CD22 Exons 10–11 and
CD22 Exons 13–14 in the 217422_s_at probeset from the median cen-
tered expression values of the 3 CD22 Exon 12 probes. We found highlysigniﬁcant reductions in Exon 12 index for primary leukemia cells in
newly diagnosed high-risk pediatric B-precursor ALL patients. 242 of
279 (87%) leukemic samples had lower CD22ΔE12-index values that
were lower than the 95% lower conﬁdence interval for the CD22ΔE12-
index values for the normal hematopoietic cells in 74 non-leukemic
control bone marrow samples (P b 0.0001). The average CD22ΔE12
index values were −0.15 ± 0.03 for the leukemia samples and
0.52 ± 0.07 for the normal bone marrow samples (Fig. 1A). Like-
wise, adult B-lineage lymphoid malignancies were characterized
by a high incidence of the CD22ΔE12 genetic defect. Leukemia/lym-
phoma cells from 497 of 621 patients with B-lineage lymphoid ma-
lignancies (80%) had lower CD22ΔE12-index values that were lower
than the 95% lower conﬁdence interval for the CD22ΔE12-index
values for the 130 normal B-cell samples (95% CI = 0.094–0.349)
(P b 0.0001). The average CD22ΔE12 index values were −0.29 ±
0.02 for the leukemia/lymphoma samples and 0.22 ± 0.01 for the
normal B-cell samples (Fig. 1B).
3.2. Signature phosphoproteome of CD22ΔE12 transgenic mouse BPL cells
The phosphoprotein proﬁles of CD22ΔE12-Tg BPL cells were com-
pared side-by-side with those of Eμ-MYC Tg BPL cells, BCR-ABL Tg BPL
cells as well as WT splenocytes from healthy C57BL/6 mice by using
the Phospho Explorer Antibody Array platform, as described in
Methods. Data were normalized utilizing the median intensity values
for the 1318 antibodies on each array. The normalized data were log10
transformed andmean centered to theWT C57BL/6 splenocyte samples
(N= 4, 2 technical replicates for each of 2 samples). 241 proteins (101
upregulated and 140 downregulated) were differentially expressed in
CD22ΔE12-Tg BPL cells (P b 0.005) (Fig. 2A). The most signiﬁcantly
overexpressed 32 proteins (represented by 34 speciﬁc antibodies)
included several proteins known for their anti-apoptotic function (e.g.
mTOR, p70S6, AKT, NFκB), transcription factors implicated in oncogen-
esis (e.g. ATF2), and serine kinase signaling pathway proteins (e.g.
MAPK, PKC, PKD) (Fig. 2B, Table S1).
3.3. CD22ΔE12-driven gene expression cassette characterizes primary
human leukemia cells
We examined the gene expression proﬁles of the CD22ΔE12-Tg,
MYC-Tag and BCR-ABL-Tag BPL cells vs. wild type normal splenocytes
using the Mouse Gene 1.0 ST oligonucleotide array platform and per-
formed linear contrasts to determine if the expression levels of any 32
genes (represented by 43 probesets) that encode differentially upregu-
lated phosphoproteins in CD22ΔE12-Tg BPL cells were also differential-
ly upregulated in CD22ΔE12-Tg BPL cells. Transcript levels were
signiﬁcantly higher in CD22ΔE12-Tg BPL cells for 10 of these 32 genes
represented by 25 probesets (Fig. S1). Notably, this 10-gene signature
transcriptome was also upregulated in Uckun et al. (2010) BPL cells
from 76 relapsed pediatric BPL patients (GSE28460 and GSE18497) vs.
normal hematopoietic cells (Fig. 3) (Ma et al., 2012), leukemic B-cells
from 578 adult CLL patients (GSE13159 and GSE39671) vs. non-
leukemic B-cells (Fig. S2), and (Uckun et al., 1987) neoplastic cells
from 38 MCL patients (GSE36000) vs. normal B-cells (Fig. 4). Mixed
Model ANOVA demonstrated signiﬁcant increases in the multivariate
means for the 25 probesets for relapsed BPL (diagnostic group effect,
F1,148 = 11.7, P = 0.0008), CLL (F1,706 = 15.7, P = 0.00008) as well
as MCL (F1,166 = 13.1, P = 0.0004). Four transcripts representing 3
genes were signiﬁcantly upregulated across all 3 patient groups of
leukemia patients (ATF2_212984_at, PLCG2_204613_at, RPS6KB1_
204171_at, RPS6KB1_226660_at). Signiﬁcant negative correlations be-
tween CD22ΔE12 index and expression of each of the 4 probesets
(PLCG2_204613_at, r = −0.35, F1,894 = 124, P b 0.0001;
RPS6KB1_204171_at, r = −0.22, F1,894 = 47, P b 0.0001;
RPS6KB1_226660_at, r = −0.18, F1,894 = 28, P b 0.0001;
ATF2_212984_at, r =−0.14, F1,894 = 17, P b 0.0001) were observed
Fig. 1. Incidence of CD22ΔE12 in pediatric and adult B-lineage lymphoid malignancies.
BLAT analysis on CD22 probe sequences for probeset 217422_s_at (covering exons
10–14) deposited in the Affymetrix NetAffx™ Analysis Center were mapped onto speciﬁc
CD22 exons and visualized using the UCSC genome browser (http://genome.ucsc.edu/cgi-
bin/hgBlat?command=start). An Exon 12 Indexwas calculated by subtracting themedian
centered expression values of the 7 probes for Exons 10–11 and Exons 13–14 from the
median centered expression values of the 3 Exon 12 probes. [A] Depicted is the dot plot
of the sample level CD22ΔE12-index values in primary leukemia/lymphoma samples
from 621 adult patients with Burkitt's lymphoma, CLL ormantle cell lymphoma/leukemia.
497 samples (80%) leukemic samples had lower CD22ΔE12-index values that were lower
than the 95% lower conﬁdence interval for the CD22ΔE12-index values for the 130 normal
B-cell samples (95% CI= 0.094–0.349) (P b 0.0001). The average CD22ΔE12 index values
were−0.29 ± 0.02 for the leukemia/lymphoma samples and 0.22 ± 0.01 for the normal
B-cell samples. [B] Depicted is the dot plot of the sample level CD22ΔE12-index values in
primary leukemia samples from 279 pediatric BPL patients and 74 normal samples (95%
CI = 0.394–0.655). 242 samples (87%) leukemic samples had lower CD22ΔE12-index
values that were lower than the 95% lower conﬁdence interval for the CD22ΔE12-index
values for the 74 normal bone marrow samples (P b 0.0001). The average CD22ΔE12
index valueswere−0.15± 0.03 for the leukemia samples and 0.52± 0.07 for the normal
bone marrow samples. BL: Burkitt's lymphoma, CLL: chronic lymphocytic leukemia,
DLBCL: diffuse large B-cell lymphoma, FL: follicular lymphoma, MCL: mantle cell leukemia/
lymphoma.
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up regulation of these most differentially upregulated CD22ΔE12-
driven signature genes (Fig. S3).3.4. Effect of CD22ΔE12–14 vs. CD22WT on clonogenicity and self-renewal
rate of leukemia cell lines
CD22ΔE12 is a mis-spliced mRNA resulting from an intronic muta-
tion that skips exon 12. Translation of CD22ΔE12 sequence into proteinresults in a truncating frame shift starting at residue 736. CD22ΔE12 pro-
tein is unable to transmit apoptotic signals, as most of the intracellular
domain encoded by Exons 12–14 is lost, including the key regulatory sig-
nal transduction elements and all of the cytoplasmic tyrosine residues
(Uckun et al., 2010). In an effort to evaluate the effects of expression of
a truncated CD22 protein on the clonogenicity and self-renewal rate of
leukemia and lymphoma cell lines, we cloned wildtype full-length (FL)
human CD22 cDNA and a truncated human CD22 cDNA that lacks
exons 12–14 (CD22ΔE12–14) into the pCL6-2AEGwo lentiviral vector
containing a 2A-like peptide (Figs. S4, 5A1, A2 & B1). The expression
levels of the full-length and truncated proteins were conﬁrmed to be
similar by Western blot analysis (Fig. 5B2 & B3). Expression of GFP-
tagged full length and truncated CD22 proteins in transduced leukemia
cells was further conﬁrmed by ﬂuorescence microscopy (Fig. 5C). In
two independent experiments, lentiviral-based expression of truncated
CD22ΔE12–14 protein (but not FL CD22) in CD22ΔE12-negative
Burkitt's leukemia/lymphoma cell line DAUDI resulted in a marked in-
crease in the size of day 7 colonies on consistent with increased self-
renewal as well as increase of its in vitro clonogenicity, as measured by
increased number (per 100,000 cells) of colonies formed in semisolid
methylcellulose cultures (421 ± 83 vs. 104 ± 40, linear contrast
P-value = 0.0006) (Fig. 5C & D). Conversely, in both experiments, the
lentiviral-based overexpression of FL CD22 in CD22ΔE12-positive ALL-1
cell line virtually abrogated its clonogenic growth (8 ± 5 vs. 301 ±
103, linear contrast P-value= 0.0025). The empty vector without an in-
sert did not consistently affect the clonogenicity or self-renewal of either
cell line (Fig. 5C &D). These ﬁndings support our hypothesis that expres-
sion of a truncated human CD22 that lacks the signal transduction
elements encoded by Exons 12–14, as it occurs in CD22ΔE12+ ALL,
would confer B-lineage leukemia and lymphoma cells with a selective
growth advantage.3.5. CD22ΔE12 as a molecular target for RNAi therapy in human B-lineage
lymphoid malignancies
We ﬁrst used RT-PCR to examine the effects of transfection with
CD22ΔE12-speciﬁc siRNA on CD22ΔE12 mRNA expression levels in
CD22ΔE12+ BPL cell line ALL-1 with homozygous intronic CD22 gene
mutations at Rs10413526 (CNG) and Rs4805120 (ANG). CD22ΔE12-
siRNA (but not scrambled/scr-siRNA) caused depletion of the truncated
CD22ΔE12-mRNA (Fig. 6A). CD22ΔE12-depletion in transfected ALL-1
was associated with abrogation of in vitro proliferation and clono-
genicity, as reﬂected by a drastic decrease in the number and cellular
content of colonies formed in semi-solid methylcellulose cultures
(Fig. 6B).Wenext used aggressive BPL xenograft clones (N=3) isolated
from spleens of NOD/SCIDmice that had developed overt leukemiawith
massive splenomegaly following inoculation with primary leukemia
cells from the respective BPL patients to further evaluate the suitability
of CD22ΔE12 as a molecular target for RNAi. Immunophenotyping by
multiparameter ﬂow cytometry conﬁrmed the co-expression of multi-
ple BPL-associated human lymphoid differentiation antigens, including
high levels of CD10, CD19, and CD34 (Fig. 6C) that have been reported
as markers of putative leukemic stem cells in BPL (Uckun et al., 2013).
Transfectionwith CD22ΔE12-siRNA, but not scr-siRNA, caused selective
(albeit partial) depletion of CD22ΔE12-mRNA as well as CD22ΔE12-
protein in aggressive BPL xenograft cells (Fig. 6D). This siRNA-
mediated CD22ΔE12-knockdown was associated with a marked in-
hibition of their clonogenic growth in vitro (Fig. 6E). The mean
number of blast colonies per 100,000 (Uckun et al., 1987) BPL xeno-
graft cells plated were 186 ± 18 for untransfected control cells,
191 ± 24 for cells transfected with scr-siRNA (60 nM), and 27 ±
14 for cells transfected with CD22ΔE12-siRNA (60 nM) (P b 0.0001
vs. scr-siRNA, P b 0.0001 vs. CON). Both the proliferative activity
and clonogenicitywere inhibited, as reﬂected by the substantially small-
er number and size of the blast colonies (Fig. 6F1–F3).
Fig. 2. Signature phosphoproteome of CD22ΔE12 transgenicmouse BPL cells. The phosphoprotein proﬁles of CD22ΔE12-Tg BPL cells were compared side-by-sidewith those of Eμ-MYC Tg
BPL cells, BCR-ABL Tg BPL cells aswell asWT splenocytes from healthy C57BL/6mice by using the Phospho Explorer Antibody Array platform (Full Moon BioSystems, Inc., Sunnyvale, CA),
as described inMethods section. Data were normalized utilizing themedian intensity values for the 1318 antibodies on each array. The normalized data were log10 transformed andmean
centered to theWT C57BL/6 splenocyte samples (N= 4, 2 technical replicates for each of 2 samples). [A] Depicted is a one-way hierarchical cluster ﬁgure that illustrates phosphoprotein
expression differences between BPL cells from CD22ΔE12-Tgmice and normal splenocytes from healthyWTmice, BPL cells from BCR-ABL Tgmice or BPL cells from Eμ-MYC Tg mice. 241
proteins were differentially expressed in CD22ΔE12-Tg BPL cells (P b 0.005): 101 proteins were upregulated and 140 proteins were downregulated. Heat map depicts up and down
regulated protein expression levels ranging from red to green respectively. [B] Depicted are the most signiﬁcantly overexpressed 32 phosphoproteins (represented by 34 speciﬁc antibodies
used as probes in CD22ΔE12-Tgmice). Expression values weremean centered toWT samples and clustered according to average distancemetric. The results of the Student's T-tests (Unequal
variance correction, Microsoft Excel) comparing mean-centered, log10 transformed protein expression levels in BPL cells from CD22ΔE12-Tg mice vs. splenocytes fromWTmice and BPL cells
from BCR-ABL Tg or MYC Tg mice are detailed in supplemental Table S1.
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We recently reported a cell-penetrating cationic helical polypeptide
(termed PVBLG-8) that displays distinguished membrane disruptionand endosomal escape properties (Gabrielson et al., 2012; Lu et al.,
2011). PVBLG-8 was identiﬁed as the top-performing peptide for nucle-
oside delivery and preparation of nanoscale siRNA formulations (Yin
et al., 2013a). (Fig. S5). PVBLG-8 was synthesized via controlled ring
Fig. 3. Upregulated expression of the CD22ΔE12-driven gene expression cassette in human leukemia cells from pediatric patients with relapsed BPL. The 10-gene mouse CD22ΔE12-Tg
gene expression cassette was represented by 25 probesets on the human U133 plus 2.0 array. The RMA-normalized gene expression values for leukemia cells from 76 BPL patients in re-
lapse were log2 transformed and mean-centered to the average value for the normal hematopoietic cells (N = 74). [A] The gene expression values were clustered according to average
distance metric. Heat map depicts up and down regulated transcripts ranging from red to blue respectively for expression values mean centered to normal hematopoietic cells in non-
leukemic samples. [B] To determine the differential expression of each leading edge gene of the CD22ΔE12 transcriptome in relapsed BPL cells, linear contrasts were performed for the
RMAnormalized values (Pb 0.05 deemed signiﬁcant). Depicted are themean fold difference and linear contrast P-values relative to normal samples for the comparisons ordered according
to effect size. Mixed Model ANOVA demonstrated signiﬁcant increases in the multivariate means for the 25 probesets for Normal vs. Relapsed BPL (Diagnostic group effect, F1,148 = 11.7,
P =0.0008). Five transcripts representing 3 genes displayed greater than 2 fold increases in relapsed BPL cases (PTK2_208820_at, PTK2_241453_at, ATF2_212984_at, PLCG2_204613_at,
PTK2_1559529_at) and 12 transcripts representing 8 genes (ATF1, ATF2, MTOR, PLCG2, PTK2, RELA, RPS6KB1 and TSC2) were upregulated with P b 0.05.
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Glu-NCA), as initiated by hexamethyldisilazane (HMDS) followed by
multi-step side-chain modiﬁcation (Fig. S5A) (Gabrielson et al., 2012;
Lu et al., 2011; Yin et al., 2013a; Zhang et al., 2011). In an attempt to fur-
ther strengthen the electrostatic interactions of the cationic PVBLG-8
with the CD22ΔE12-siRNA andpromote the CD22ΔE12-siRNA encapsu-
lation in the complex nanostructure, we also included another anionic
polypeptide, PAOBLG-MPA (Zhang et al., 2011) in the formulation at
a PVBLG-8:PAOBLG-MPA:CD22ΔE12-siRNA weight ratio of 10:2:1
(Fig. S5B). By using this formulation strategy, we have successfully
complexed CD22ΔE12-siRNA with a 200-mer polymer of PVBLG-8 toprepare a nanoscale formulation of CD22ΔE12-siRNA (Fig. 7D). This
unique nanoparticle formulation effectively delivered Cy3-labeled
CD22ΔE12-siRNA into the cytosol of ALL-1 cells (Fig. 7E), caused
marked CD22ΔE12 depletion, as determined by RT-PCR with the P7
primer pair (Fig. 7F) and inhibited their clonogenic growth in vitro
(Fig. 7G). At both concentrations used, its inhibition of the ALL-1
clonogenicity (96.6% at 66 nM and 99.94% at 200 nM) was much more
pronounced than the non-speciﬁc effects of the scr-siRNA formulation
(34.2% at 200 nM) (Fig. 7G). The linear contrast P-values for
CD22ΔE12-siRNA NF vs. CON + scr-NF were 9 × 10−10 for 66 nM and
4 × 10−10 for 200 nM.
Fig. 4. Upregulated expression of the CD22ΔE12-driven gene expression cassette in human leukemia cells from adult patients with MCL. The 10-gene mouse CD22ΔE12-Tg gene expres-
sion cassette was represented by 25 probesets on the human U133 plus 2.0 array. The RMA-normalized gene expression values for leukemia cells from 38 patients with MCL were log2
transformed and mean-centered to the average value for the normal B-cells (N = 130). [A] The gene expression values were clustered according to average distance metric. Heat map
depicts up and down regulated transcripts ranging from red to blue respectively for expression values mean centered to normal B-cells in non-leukemic samples. [B] To determine the
differential expression of each leading edge gene of the CD22ΔE12 transcriptome in MCL cells, linear contrasts were performed for the RMA normalized values (P b 0.05 deemed signif-
icant). Mixed model ANOVA demonstrated signiﬁcant increases in the multivariate means for the 25 probesets for Normal vs. MCL (diagnostic group effect F1,166 = 13.1, P = 0.0004).
Depicted are the mean fold difference and linear contrast P-values relative to normal samples for the comparisons ordered according to effect size. Four transcripts representing
3 genes were signiﬁcantly up regulated greater than 2-fold (RPS6KB1, ATF2, PLCG2) and 15 transcripts representing 8 genes were up regulated with P-values b 0.05 (ATF1, ATF2,
ATP1A1, MTOR, PLCG2, PTK2, RELA and RPS6KB1).
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Fig. 5. Effect of CD22ΔE12 vs. CD22WT on clonogenicity and self-renewal rate of ALL cells. [A1] Depicted is a representative 1% agarose gel showing the PCR products of FL CD22 and
CD22ΔE12–14. [A.2] Subcloning of the CD22 FL or CD22ΔE12–14 genes into the lentiviral pCL6-2AEGwo vector through NheI and XhoI restriction sites was conﬁrmed through restriction
enzyme digestion and DNA sequencing. Depicted is a representative 1% agarose gel showing that the generated lentiviral constructs have the correct size FL CD22 (2.5-kb) or CD22ΔE12–
14 (2.2-kb) inserts. [B.1] In order to conﬁrm that the lentiviral vectors can be used to achieve expression of FL and truncated CD22 inhuman cells, 293T cellswere transfectedwith lentiviral
constructs for FL CD22, CD22ΔE12–14, as well as pCL6-2AEGwo lentiviral vector without any subcloned CD22. 48 h post transfection cells were examined for FL CD22 and CD22ΔE12–14
mRNA by RT-PCR using the P7, P9, and P10 primer pairs. The P7 primer setwas used to amplify a 182-bp region (c.2180–c.2361) of the CD22 cDNA extending fromExon 11 to Exon 13 and
spanning the entire Exon 12. The P9 primer set was used amplify a 160-bp region (c.2304–c.2463) of the CD22 cDNA extending from Exon 12 to Exon 14 and spanning the entire Exon 13.
The P10primer setwas used to amplify a 213-bp region (c.433–c.645) of Exon 4 of the CD22 cDNApresent in bothwildtype CD22 andCD22ΔE12–14mRNA species. As expected all primer
sets yielded PCR products in cells transfectedwith the FL CD22 vector and only the P10 primer set yielded a PCR product in cells transfectedwith the CD22ΔE12–14 vector. [B.2 and B3] The
increased expression levels of the full-length and truncated proteins in transduced 293-T cells (depicted in B.2) and ALL-1 cells (depicted in B.3) were conﬁrmed to be similar byWestern
blot analysis done at 96 h post-transduction. [C & D] ALL cell lines DAUDI (Burkitt's leukemia/B-ALL) (panels C1 & C.2) and ALL1 (BCR-ABL+ B-precursor ALL) (panel C3) were transduced
(trans) with wildtype and mutant human CD22 genes using the pCL6-2AEGwo lentiviral vector and then assayed for colony formation in semi-solid methylcellulose cultures without
additional stroma support or cytokines. Colony formation was examined using an inverted Nikon Eclipse TS100 microscope with an Epiﬂuorescence attachment. Images were taken
using a Digital Sight DS-2MBW Nikon camera (System magniﬁcation: 100× or 200× as indicated). Green ﬂuorescence of colonies resulting from GFP expression conﬁrms successful
transduction of the cell lines. [D] Depicted are bar graphs comparing the mean colony numbers in cultures of untransduced and transduced cells.
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The major challenge in the treatment of BPL is to cure patients who
have relapsed despite intensive frontline chemotherapy. There is an
urgent and unmet need to identify new drug candidates capable of
destroying chemotherapy-resistant leukemic B-cell precursors (BCP).
Our recent ﬁndings have implicated CD22ΔE12 arising from a splicing
defect associated with homozygous intronic mutations as a previously
undescribed pathogenic mechanism in human BPL (Uckun et al.,
2010). CD22ΔE12 is the ﬁrst reported genetic defect implicating a
B-cell co-receptor in a human lymphoid malignancy and linking homo-
zygousmutations of the CD22 gene to a human disease and also theﬁrstgenetic defect implicating intronicmutations in the pathogenesis of leu-
kemia. The abnormal CD22ΔE12 protein is encoded by a profoundly
aberrant mRNA arising from a splicing defect that causes the deletion
of exon 12 (c.2208–c.2327) (CD22ΔE12) and results in a truncating
frame shift mutation. Our overarching objective in this project was to
design an innovative and effective strategy that would utilize the
CD22ΔE12 genetic lesion as a molecular target to gain a therapeutic ad-
vantage against chemotherapy-resistant aggressive BPL. Speciﬁcally, we
sought to validate CD22ΔE12 as an effective molecular target for RNA
interference (RNAi) therapy in BPL. Transfection of leukemia cells with
CD22ΔE12-speciﬁc siRNA caused effective depletion of the truncated
CD22ΔE12-mRNA. CD22ΔE12-depletion was a drastic inhibition of the
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aggressive leukemia xenograft clones. These results provided unprece-
dented evidence that the CD22ΔE12 genetic defect can be leveraged
as a molecular target for RNAi therapy against B-lineage lymphoid
malignancies.
Nanoparticles represent particularly attractive delivery systems for
small interfering RNA (siRNA) and may provide the foundation for ra-
tional design and formulation of RNAi-triggering nanomedicines. We
recently developed a platform for the facile generation of cationic helical
polypeptides (termed PVBLG), which was realized by maintaining aseparation distance of 11 σ-bonds between the peptide backbone and
the side chain charge (Gabrielson et al., 2012; Lu et al., 2011). Based
on this strategy, a library of cationic polypeptides with purposely de-
signed, stable helical structures were prepared. Like cell-penetrating
peptides found in nature, these cationic helical polypeptides displayed
distinguished membrane disruption/destabilization properties. Subtle
changes of side chains allowed the generation of polypeptides with ap-
propriate DNA binding strength as well as endosomal escape capacity.
PVBLG-8 was identiﬁed as the top-performing peptide for gene trans-
fection (Gabrielson et al., 2012; Lu et al., 2011; Yin et al., 2013a). We
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cently provided the ﬁrst preclinical proof of principle that this helical
polypeptide is uniquely suited for preparation of nanoscale siRNA
formulations (Yin et al., 2013a).
In the present study, we used a polymer of PVBLG-8 to prepare a
nanoscale formulation of CD22ΔE12-siRNA. PVBLG-8 with its long
back-bone length and high charge density provided the desired afﬁnity
for the oppositively charged siRNA molecules, whereas the helical
secondary structure of PVBLG-8 was designed to facilitate the delivery
of siRNA into leukemia cells and their escape from the endosomal/
lysosomal compartments. The nanoparticle formulation was highly ef-
fective in knocking down the expression of CD22ΔE12 and killing
clonogenic leukemia cells. Further development and optimization of
this RNAi therapeutic candidate targeting CD22ΔE12 may facilitate a
paradigm shift in therapy of aggressive or chemotherapy-resistant
B-lineage lymphoid malignancies.
A more rapid development of nanoscale RNAi therapeutics has been
hampered by the limited knowledge about the identity of the critical
driver lesions in speciﬁc types of cancer, safety concerns about certain
formulations, and a disappointingly poor delivery of the siRNA into
target cancer cells (Guo &Huang, 2011). Only a limited number of poly-
meric materials have been tested in clinical trials for their capability of
delivering siRNA into human cancer cells. Examples include the linear
cyclodextrin polycations developed by Mark Davis at Caltech/Calando
Pharmaceuticals (Davis et al., 2010) and the siG12D LODER (a proprie-
tary biodegradable polymeric matrix) developed by Silenseed Science
and Technology (Burnett et al., 2011). There is an urgent and unmet
need to identify novel materials and delivery systems capable of safely
and efﬁciently delivering siRNA to molecular targets not amenable to
other drug-delivery approaches. The described siRNA delivery platform
is based on a class of rationally designed cell-penetrating cationic helical
polypeptides (Gabrielson et al., 2012; Lu et al., 2011; Yin et al., 2013a;
Zhang et al., 2011). These polypeptide-based novel nanomaterials ex-
hibit unprecedented thermodynamic and physicochemical stability
(Gabrielson et al., 2012; Lu et al., 2011; Yin et al., 2013a; Zhang et al.,
2011) and unique biological properties with an exceptional endosomal
escape and siRNA delivery efﬁciency (Gabrielson et al., 2012; Lu et al.,
2011; Yin et al., 2013a; Zhang et al., 2011). Nanoparticles have been
coated with polyethylene glycol (PEG) (i.e., PEGylated) to enhance
their biocompatibility and improve their pharmacokinetics. PEGylated
NP with diameters around 100 nm can evade recognition and rapid
clearance by macrophages and other elements of the reticuloendo-
thelial system (RES) (Uckun& Yiv, 2012; Davis et al., 2008).We recently
reported that the incorporation of PEG further improved thebiocompat-
ibility and safety proﬁle of the helical PVBLG-8 block without dramati-
cally compromising the polymer's ability to destabilize membranesFig. 6. CD22ΔE12 siRNA induced selective depletion of aberrant CD22ΔE12 mRNA species. [A]
C005)with either CD22ΔE12-siRNA or scr-siRNA. Controls includeduntreated cells. Depicted is
of CD22ΔE12-siRNA transfected ALL-1 cells using the P7 primer pair to amplify a 182-bp region
entire Exon 12. Deletion of Exon 12 results in a smaller CD22ΔE12-speciﬁc PCR product of 63-bp
set was used as a positive control of RNA integrity to amplify a 213-bp region (c.433–c.645) of
siRNA but not scr-siRNA caused depletion of the CD22ΔE12mRNA. [B] Depicted are themean n
(66 nMor 200nM) or scr-siRNA (200nM). Controls includeduntreated cells (CON). [C] Depicted
from spleens of NOD/SCID mice that developed overt leukemia after inoculation with primary
lymphoid differentiation antigens CD10, CD19, CD34, CD45, HLA-DR/DP/DQ, and HLA-A,B,C. T
CD45, HLA-DR/DP/DQ and HLA-A,B,C antigens and had an immature B-cell precursor immuno
CD19, and CD34. [D] Depicted is the image of a 1% agarose gel showing the RT-PCR product
using the P7 primer pair. The P10 primer set was used as a positive control of RNA integrity.Wh
blot analysis. The positions of truncatedmutant CD22ΔE12 protein and TUB are indicatedwith a
instead of the 130/140-kDa intact CD22 protein. Transfectionwith CD22ΔE12-siRNA, but not scr
protein in aggressive BPL xenograft cells. [E] Thebar graphsdepict themean±SEvalues for blas
xenograft cells formed 186 ± 9 colonies, CD22ΔE12-siRNA transfected xenograft cells formed
formed 191± 24 colonies, which was not signiﬁcantly different from the colony numbers obta
tures of CD22ΔE12-siRNA transfected xenograft cells (P b 0.0001). [F] Colony formationwas exa
ital Sight DS-2MBW Nikon camera. Depicted are images of blast colonies demonstrating that
colonies.(Yin et al., 2013b; Yen et al., 2013). Furthermore, polymer physicochem-
ical properties, especially the 3-dimensional structure, have a signiﬁcant
impact on their membrane penetration and siRNA delivery efﬁciencies
of cationic polypeptides. We recently discovered that a star-shaped
PEG-PVBLG-8 copolymer adopting a spherical architecture with high
density of PPVLG-8 had the highest membrane-permeabilizing activity
and reduced cytotoxicity which contributed to its potent “transfection”
efﬁciency (Yin et al., 2013b). Therefore, we plan to use the star copoly-
mer in preparation of the next generation of PVBLG-8 based nano-
particles. We hypothesize that siRNA nanocomplexes prepared using
reconﬁgured PVBLG-8 building blocks, especially PEG-PVBLG-8 star co-
polymers with a spherical architecture and high density of PVBLG-8
(Yin et al., 2013b), will exhibit unprecedented in vivo RNAi potency
owing to improved serum stability, pharmacokinetic properties,
biodistribution and cellular uptake. The development of polypeptide-
based multi-functional nanocomplexes with therapeutic siRNA
targeting a driver lesion such as the CD22ΔE12-speciﬁc siRNA will
be a signiﬁcant step forward to overcome chemotherapy resistance
in BPL and other CD22ΔE12+ B-lineage lymphoid malignancies.
The expression of CD22 on leukemic B-cell precursors hasmotivated
the development and clinical testing of CD22-directed MoAb, recombi-
nant fusion toxins and antibody-drug conjugates as therapeutic agents
against BPL in children (D'Cruz & Uckun, 2013). However, these thera-
peutic modalities all target the surface epitopes of CD22 and do not dis-
criminate between normal B-cells expressing intact CD22 and BPL cells
expressing CD22ΔE12. Due to the presence of CD22 on normal human
B-cells and B-cell precursors, lymphotoxicity with reduced B-cell num-
bers and possible hypogammaglobulinemiawith an increased risk of in-
fections would be anticipated side effects of CD22 directed MoAb and
MoAb based therapeutics in clinical settings. In contrast, RNAi therapeu-
tics targeting CD22ΔE12 would only kill BPL cells while leaving normal
B-cell precursors and B-cells with an intact CD22 encoded by awildtype
CD22 mRNA unharmed.
Our ﬁrst proof-of-principle showed that the helical polypeptide
PVBLG-8 is uniquely suited for preparation of siRNA NP by using the
TNFα gene as a target for RNAi (Yin et al., 2013a). Importantly, these he-
lical polypeptide hybrid NP carrying TNFα-speciﬁc siRNA displayed
membrane-disruptive and endosomolytic properties, did not cause he-
molysis at ≤50 μg/mL polypeptide concentrations, and exhibited a
promising safety proﬁle in mice with no signs of organ speciﬁc toxicity
in mice at 50 μg/kg (3.5 nmol/kg) or 500 μg/kg (35 nmol/kg) dose
levels (Yin et al., 2013a). Based on the recent identiﬁcation of TNFα as
a potentially very importantmolecular target for RNAi therapy in leuke-
mia (Kagoya et al., 2014), further development of the TNFα-siRNA har-
boring nanoparticles holds signiﬁcant translational promise because of
their anti-inﬂammatory, anti-angiogenic, and anti-leukemic potential.Cells were transfected with a Nucleofector II device (Amaxa GmbH; protocol VCA-1002/
the image of a 1% agarose gel showing the RT-PCRproducts obtained from theRNA samples
(c.2180–c.2361) of the CD22 cDNA extending from Exon 11 to Exon 13 and spanning the
size with this primer setmigrating slightly below the 100-bp sizemarker. The P10 primer
the CD22 cDNA present in both wildtype CD22 and CD22ΔE12 mRNA species. CD22ΔE12-
umbers of colonies per 100,000 ALL-1 cells plated after transfectionwith CD22ΔE12-siRNA
are representative FACS-correlated two-parameter displays of BPL xenograft cells isolated
ALL cells from BPL patients. Cells were stained by direct immunoﬂuorescence for human
he labeled cells were analyzed on a LSR II ﬂow cytometer. Xenograft cells co-expressed
phenotype characterized by co-expression of B-lineage progenitor antigens CD10/CALLA,
obtained from the RNA sample of CD22ΔE12-siRNA (50 nM) transfected xenograft cells
ole cell lysates of xenograft cells were subjected to CD22 and alpha-tubulin (TUB)Western
rrowheads. BPL xenograft cells expressed a CD22ΔE12-associated truncated CD22 protein
ambled (scr)-siRNA, caused selective depletion of CD22ΔE12-mRNA aswell as CD22ΔE12-
t colonies per 100,000 cells plated for all ALL xenograft clones (N=3).While untransfected
only 27 ± 14 colonies (P b 0.0001). By comparison, scr-siRNA transfected xenograft cells
ined in cultures of untransfected cells (P = 0.8) but signiﬁcantly higher than those in cul-
mined using an inverted Nikon Eclipse TS100microscope. Imageswere taken using a Dig-
CD22ΔE12-siRNA transfection results in reduction of the number as well as size of blast
Fig. 7. PVBLG-8-based nanoformulation (NF) of CD22ΔE12-siRNA. [A] Chemical structure of the 200-mer polymer of PVBLG-8 that we used to complex siRNA as recently published
(Gabrielson et al., 2012; Lu et al., 2011; Yin et al., 2013a). The MW for each repeating unit is 430. [B & C] Determination of the siRNA content using the standard Quant-iT RiboGreen
RNAassay (Invitrogen) and a SynergyHTBiotekﬂuorescencemicroplate reader tomeasure the siRNA content. The standard curve is depicted inB. [D] DLS curve of the complex conﬁrming
that we achieved a nanoscale formulation. [E1 & E2] We used 5' Cy3-labeled CD22ΔE12-siRNA to prepare a CD22ΔE12-siRNA “nanoparticle” formulation (NPF) for cellular uptake and
trafﬁcking experiments using confocal imaging, as described in Fig. 4. After incubation with the PVBLG-8 based formulation of Cy3-labeled siRNA for 6 h, the internalized Cy3-labeled
CD22ΔE12-siRNA was detected and localized using the TRITC ﬁlter sets. Arrowheads in DAPI/tubulin/siRNA merge images point to location of Cy3-labeled siRNA molecules inside the
DAPI-stained (blue) nucleus and -containing (green) perinuclear cytoplasm. [F] RT-PCR was performed with the P7 primer pair as in Fig. 2 (Ma et al., 2012). [G] 100,000 ALL-1 cells
were plated in duplicate dishes inmethylcellulose cultures containing noNPF (CON), 66 nMor 200 nMof the CD22ΔE12-siRNANPF, or 200 nMof the scrambled (scr)-siRNANPF. Colonies
were counted after 7 days. Depicted are bar graphs showing themean clonogenic units per 100,000 cells platedusing the cumulative data from3 experiments. Themean±SE valueswere
322.0 ± 32.1 for CON, 211.8 ± 28.3 for 200 nM scr-siRNA NPF, 10.8 ± 4.3 for 66 nM and 0.2 ± 0.2 for 200 nM CD22ΔE12-siRNA NPF.
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